Verrica Pharma Files 8-K

TL;DR

Verrica Pharma filed an 8-K on Nov 20, 2024, updating corporate info.

AI Summary

Verrica Pharmaceuticals Inc. filed an 8-K on November 20, 2024, to report other events and financial statements. The filing details the company's principal executive offices located at 44 West Gay Street, Suite 400, West Chester, PA 19380, and its principal business operations in pharmaceutical preparations.

Why It Matters

This 8-K filing provides an update on Verrica Pharmaceuticals' corporate information and financial reporting, which is crucial for investors to stay informed about the company's status.

Risk Assessment

Risk Level: low — This filing is a routine corporate update and does not appear to contain significant new risks or material adverse information.

Key Players & Entities

• Verrica Pharmaceuticals Inc. (company) — Registrant
• November 20, 2024 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of Incorporation
• 463137900 (number) — IRS Employer Identification No.
• 44 West Gay Street , Suite 400 West Chester , PA 19380 (address) — Address of Principal Executive Offices
• (484) 453-3300 (phone_number) — Registrant's telephone number

FAQ

Key Financial Figures

• $0.0001 — related to the Company's common stock, $0.0001 par value per share (the " ATM Prospect

Filing Documents

• d907739d8k.htm (8-K) — 31KB
• d907739dex991.htm (EX-99.1) — 8KB
• d907739dex992.htm (EX-99.2) — 12KB
• g907739g1120173018995.jpg (GRAPHIC) — 3KB
• 0001193125-24-262615.txt ( ) — 187KB
• vrca-20241120.xsd (EX-101.SCH) — 3KB
• vrca-20241120_lab.xml (EX-101.LAB) — 18KB
• vrca-20241120_pre.xml (EX-101.PRE) — 11KB
• d907739d8k_htm.xml (XML) — 4KB

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "anticipates," "believes," "expects," "intends," "projects," "plans," and "future" or similar expressions are intended to identify forward-looking statements. Forward-looking statements include statements concerning the Company's anticipated public offering, including the uncertainties related to market conditions and the completion of the public offering on the anticipated terms, if at all. Forward-looking statements are based on management's current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding the Company's business are described in detail in its SEC filings, including in the Company's Annual Report on Form 10-K for the full-year ended December 31, 2023, and the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, which are available on the SEC's website at www.sec.gov. Additional information will be made available in other filings that the Company makes from time to time with the SEC. These forward-looking statements speak only as of the date hereof, and the Company disclaims any obligation to update these statements except as may be required by law. Item9.01

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Description 99.1 Press Release, dated November 20, 2024. 99.2 Additional Business Information and Risk Factors. 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Verrica Pharmaceuticals Inc. Date: November 20, 2024 /s/ John J. Kirby John J. Kirby Interim Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR